SLAS Appoints New Journal Editor-in-Chief

As JALA Deputy Editor-in-Chief, Dr. Chow will work closely with JALA Editor-in-Chief Dean Ho, Ph.D., of the University of California, Los Angeles, throughout 2014 to transition planning initiatives and management responsibilities. Dr. Ho will end his tenure and Dr. Chow will assume full responsibilities as JALA Editor-in-Chief effective Jan. 1, 2015.

The Editor-in-Chief is the principal architect and arbiter of JALA’s scientific content. The Editor-in-Chief leads the strategic advancement of JALA’s scientific content in line with the SLAS mission and goals; and actively seeks and solicits the best science from the best scientists to be published in JALA.

“We are impressed with Dr. Chow’s energy and vision for JALA,” says SLAS CEO Greg Dummer. “Ed has been an active volunteer leader, serving JALA as an associate editor, guest editor, editorial board member, author and manuscript reviewer. He also has conducted Author Workshops and made scientific presentations at SLAS Annual Conferences. Plus, Ed’s first-hand understanding of scientific communities beyond the U.S., particularly in Asia, directly supports the priorities of the SLAS Strategic Plan.”

Dr. Chow received his Ph.D. in Molecular Biology from the University of California, Los Angeles; and his B.A. in Molecular and Cell Biology-Immunology from the University of California, Berkeley. Dr. Chow worked as a postdoctoral fellow in Nobel Laureate in Medicine J. Michael Bishop’s laboratory at the University of California, San Francisco; and was a co-founder and board member of Biotic Laboratories, Culver City, Calif.

Since 2012, Dr. Chow has held the position of assistant professor/junior principal investigator with the Cancer Science Institute of Singapore, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore.

Dr. Chow’s research focuses on Cancer Stem Cells: Markers, Mechanisms and Nanomedicine, including identification of markers for hepatic tumor initiating cells; molecular mechanisms behind how specific oncogenes form these cells; and evaluation of nano-based drug delivery platforms to target cancer stem cells.